Weici Tech Launches World's First 64-Channel Liquid-Helium-Free Magnetocardiography System, Miracle MCG® Pro

On May 26, 2023 (Beijing Time), Beijing X-Magtech Technologies Co., Ltd. (hereinafter referred to as “X-Magtech”) officially launched the world’s first 64-channel liquid-helium-free magnetocardiography system, Miracle MCG.^® Pro。

The World’s First 64-Channel Cryogen-Free Magnetocardiography System: Miracle MCG^® Pro

The launch of this 64-channel helium-free magnetocardiography (MCG) system marks another major milestone for X-Magtech within less than a year, following its approval last year of China’s first and the world’s second 36-channel helium-free MCG system, signifying the company’s achievement in transitioning fromKeeping Pace with Global Leading StandardstoLeading the Global Development of Cryogen-Free Magnetocardiographybreakthrough.

Miracle MCG^®Pro isThe World's First Liquid-Helium-Free Magnetocardiograph Equipped with a 64-Channel Magnetocardiographic Detector, the new architecture design addresses the technical challenges posed by high-density magnetocardiography (MCG) detection arrays. By innovatively employing an active closed-loop tracking and compensation system to ensure zero crosstalk between detectors, it achieves a globally leading millimeter-level spatial resolution for more refined cardiac magnetic field analysis. Meanwhile, it meets the clinical need to cover the entire heart and its surrounding magnetic fields across individuals of varying body types, enabling the acquisition of more comprehensive information on cardiac electrical activity. This empowers clinical experts to explore and expand the application of MCG systems in innovative areas such as the diagnosis of myocardial ischemia and arrhythmias, localization of electrophysiological abnormal foci, and diagnosis of fetal congenital heart disease.

To date, X-Magtech possesses certified products that have been implemented in multiple authoritative hospitals.36-Channel Cryogen-Free Magnetocardiography System, for scientific research and exploration of adult and fetal magnetocardiography64-Channel Cryogen-Free Magnetocardiography System, andCryogen-Free Magnetoencephalography System Supported by the National Key R&D Program, establishedComprehensiveBiomagnetic Imaging Solution Suite, which also demonstrates X-Magtech’s sustained innovation strength and product commercialization capabilities after breaking the foreign monopoly on core technologies for ultra-weak magnetic field measurement.

Miracle MCG^®Pro: The World’s First 64-Channel High-Density Magnetocardiography Detection Array

Magnetocardiography (MCG) is a non-invasive, radiation-free diagnostic technique for assessing myocardial electrical activity, suitable for a broad population including pregnant women. It does not apply any physical fields to the body; instead, it passively detects magnetic field signals generated by cardiac electrical activity, ensuring a noise-free and contactless examination.

Since magnetic field propagation is not subject to attenuation or interference by human tissues and provides detailed information such as magnitude and direction, it offers advantages over electrocardiographic measurements, including higher sensitivity, absence of signal attenuation, and localization capability. Therefore, it can be used for functional diagnosis and prognostic studies of conditions such as myocardial ischemia, myocardial injury, arrhythmias (particularly ventricular arrhythmias, atrial fibrillation, Brugada syndrome, and fetal arrhythmias), and cardiomyopathy.

Since the first measurement of the human cardiac magnetic field in 1962, magnetocardiography (MCG) has evolved for over 60 years. Prior to 2019, the field was dominated by Superconducting Quantum Interference Device (SQUID) technology. However, its widespread clinical adoption was hindered by several limitations: the need for liquid helium to maintain superconducting temperatures, high costs associated with magnetic shielding, susceptibility to electromagnetic interference in hospital environments without adequate shielding, the requirement for ECG gating, and prolonged measurement times ranging from 5 to 15 minutes. Consequently, SQUID-based MCG was primarily utilized in research settings. Currently, both domestically and internationally, the predominant technology is the 9-channel unshielded superconducting magnetocardiograph.

Liquid-helium-free magnetocardiography (MCG) represents an emerging technological pathway. In 2019, Genetesis, a U.S. technology innovation company, launched an innovative 36-channel liquid-helium-free MCG system based on novel quantum magnetic field measurement technology developed at Princeton University. This system received FDA 510(k) clearance and was twice designated as an FDA Breakthrough Imaging Device in 2020 and 2022. It has been deployed in clinical applications at renowned medical institutions, including the Cleveland Clinic.

In 2022, X-Magtech based onProprietary Quantum Magnetic Field Sensing Technology – Atomic Magnetometer, successfully launchedThe 36-channel liquid-helium-free magnetocardiography system, which obtained the first medical device registration certificate in China and the second globally,and inBeijing Anzhen Hospital, Capital Medical University / National Clinical Research Center for Cardiovascular Diseases、Xiangya Hospital of Central South University、Guangdong Provincial People's HospitalUsed by leading hospitals.

Atomic magnetometer technology is one of the quantum precision sensing technologies, due to its high sensitivity of up to 10^-15With its sensitivity in the tesla range, compact size comparable to a USB flash drive, and ability to operate at room temperature, it has become one of the most promising and widely discussed technologies for biomagnetic field measurement.

X-Magtech broke the U.S. monopoly in 2021 by launching a fully domestically produced product, andEstablished multiple core production lines, including raw material preparation, optoelectronic chip packaging and testing, and atomic vapor cell filling., ensuring that future magnetoencephalography (MEG) and magnetocardiography (MCG) systems are not constrained by foreign supply chain bottlenecks, thereby removing barriers to the clinical adoption of these products in China and enabling broader patient access.

Due to the high technical complexity of atomic magnetometer products and the weak signals they measure, particularly the crosstalk prone to occur during close-range multi-channel operation, it is difficult to achieve high-density deployment. Consequently, the spatial resolution of magnetic field imaging is limited, preventing more refined cardiac functional imaging and lesion localization. X-Magtech has innovatively appliedActive Closed-Loop Tracking and Compensation SystemandHigh-Speed Digital Signal Processing Technology, overcoming the challenges of crosstalk and control in high-density, multi-channel atomic magnetometer arrays, achieving64-Channel High-Speed Synchronous Magnetocardiography Measurement with Zero Crosstalk。

The launch of this world-first 64-channel product demonstrates thatSpatial Resolution of Cardiac Magnetic Field Measurement Reaches Millimeter Scale, marking X-Magtech’s leap from following to leading the global development of liquid-helium-free magnetocardiography systems.

64-Channel Cryogen-Free Magnetocardiography System Miracle MCG^® Pro enables non-invasive, radiation-free, and contrast-agent-free functional cardiac imaging in 90 seconds.

X-Magtech's 36/64-Channel Cryogen-Free Magnetocardiography System,No ECG gating required; cardiac magnetic field measurement and imaging can be completed in 90 seconds.. Meanwhile, as the system integrates a high-performance magnetic shielding system and multiple noise reduction algorithms, there is no need to build additional shielding facilities; it can operate stably within the electromagnetic environment of hospitals, ensuring the validity of each detection. Currently, it has been successively installed and put into use in many top-tier Grade-A tertiary hospitals and authoritative cardiovascular hospitals across China, where numerous clinical studies have been conducted, accumulating thousands of clinical cases.

In terms of application scenarios, given the rapid, non-invasive, and radiation-free characteristics of cryogen-free magnetocardiography (MCG) systems, they are suitable for:

Non-invasive Diagnosis of Coronary Heart Disease——Currently, the non-invasive imaging techniques for coronary heart disease commonly used in clinical practice in China are primarily coronary CTA and SPECT myocardial perfusion imaging. Miracle MCG^®Can be provided in combination with CTANon-invasive Functional Imaging + Morphological Information, thereby improving diagnostic accuracy. It is particularly valuable for patients with calcified lesions or those in whom CTA diagnosis is challenging following stent implantation, providing a basis for clinical decision-making by specialists prior to further invasive examinations.

Detection of Myocardial Ischemia Caused by Coronary Microcirculatory Dysfunction——Due to Miracle MCG^®The diagnosis of myocardial ischemia is based on the functional status of cardiomyocytes, rather than merely on the assessment of the degree of stenosis in epicardial vessels. Therefore, upon achieving millimeter-level spatial resolution, it becomes possible to detect myocardial ischemia caused by microcirculatory dysfunction, providingA Non-invasive, Effective, and User-friendly Diagnostic Tool for Coronary Microcirculation。

Pharmacological Intervention, Post-PCI, and Long-Term Monitoring for Cardiac Rehabilitation Patients—Based on Miracle MCG^®Its fully non-invasive nature and immunity to interference from implanted stents make it suitable for drug intervention, post-PCI follow-up, and long-term monitoring of cardiac rehabilitation patients. This addresses patient concerns about the physical harm associated with repeat CTA or coronary angiography, enabling continuous and close monitoring of disease progression or recovery.

Screening for Coronary Heart Disease in Healthy Populations——A 90-second examination with instantly visible results is suitable for large-scale screening of coronary heart disease in healthy populations, providing early warning of myocardial ischemia risk to enable early detection, prevention, and treatment.

Additionally, in terms of scientific research and exploration, Miracle MCG^®Also indicated for:

Arrhythmia Focus Localization—By leveraging the vector nature of magnetocardiographic signals (which possess both magnitude and direction) in conjunction with a 36/64-channel high-density detection array, precise localization of atrioventricular accessory pathways and ectopic pacemakers can be achieved, providing more accurate reference information for pre-operative radiofrequency ablation. This technology can also detect conditions such as complex arrhythmias complicated by myocardial ischemia, which are not effectively identifiable by conventional electrocardiography.

Fetal Arrhythmia Detection—The fetus is protected by amniotic fluid and the amniotic membrane within the uterus, making it difficult to capture detailed fetal cardiac electrical activity using conventional adult electrocardiography (ECG) techniques. Since magnetic field signals propagate without being affected by human tissues, fetal magnetocardiographic (MCG) signals can be acquired at the maternal body surface with a high signal-to-noise ratio. Miracle MCG^®Detection sensitivity reaches 10^-14X-Magtech enables non-invasive monitoring of fetal cardiac electrical activity during pregnancy, offering new insights for the diagnosis of congenital heart diseases such as fetal arrhythmias. The American Heart Association has included this technology in its guidelines for the evaluation of fetal arrhythmias.

X-Magtech’s core competitiveness lies in its independent and controllable core technologies and supply chain, coupled with clinical applications at numerous top-tier Grade A tertiary hospitals in China and endorsement by authoritative experts. These factors have enabled the company to rapidly catch up with and surpass international standards within a short period. Benefiting from strong national support for the independent research, development, and application of high-end innovative medical devices, X-Magtech is accelerating the deployment of its liquid-helium-free magnetocardiography (MCG) and magnetoencephalography (MEG) systems. These innovations provide powerful diagnostic tools for major cardiovascular and cerebrovascular diseases, benefiting the broad Chinese population and contributing to the ambitious goals of Healthy China 2030.

X-Magtech's Liquid-Helium-Free Magnetocardiography Imaging Solution